

Itraconazole Therapy In Bronchiectasis With Airway Mold

NCT07283497

Status	RECRUITING
Phase	Phase 4
Sponsor	Mayo Clinic
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Age ≥18 years seen at Mycobacterial and Bronchiectasis Clinic (MMBC) in Rochester
- Diagnosis of bronchiectasis confirmed by MMBC provider and chest CT
- Within the last 3 months - culture growth of a mold in high quantity ('many') or culture growth of at least two distinct mold species in any quantity
- Not actively on antimicrobial therapy AND no current plan to initiate antimicrobial therapy at the time of enrollment, as determined by treating provider
- Ability to produce spontaneous sputum at Visit 1.

Exclusion (8)

- Known diagnosis of allergic bronchopulmonary aspergillosis or invasive fungal disease
- Use of the following medications: rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, dofetilide, quinidine, dronedarone, simvastatin, lovastatin, certain immunosuppressants (tacrolimus, cyclosporine, sirolimus, everolimus) and anti-coagulants (rivaroxaban, apixaban, edoxaban, warfarin).
- Abnormal baseline liver function tests (ALT, AST, alkaline phosphatase, or bilirubin > upper limit of normal)
- Prolonged QTc interval on baseline ECG (>460 ms in females or >450 ms in males)
- History of congestive heart failure (black box warning), known cardiomyopathy, or arrhythmias
- ... and 3 more (see full listing online)

Locations (1 total)

Mayo Clinic in Rochester, Rochester, Minnesota, United States